What type of drug does Lorlatinib/Lorlatinib (Borina) belong to?

Lorlatinib/Lorlatinib (Lorlatinib) is a targeted drug, a tyrosine kinase inhibitor (TKI), mainly used to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It plays an important role in the treatment of ALK-positive lung cancer by specifically inhibiting the ALK signaling pathway and blocking the proliferation and metastasis of tumor cells.

In tumor cells, ALK gene mutations or rearrangements often lead to abnormal tyrosine kinase activity, thereby promoting tumor growth and spread. Lorlatinib, as a drug targeting ALK, can effectively prevent the proliferation and expansion of cancer cells by inhibiting the activity of ALK tyrosine kinase. In addition, lorlatinib can also act on several other oncogenes, such as the ROS1 gene, further expanding its therapeutic scope.

Compared with otherALK inhibitors (such as crizotinib, ametinib, etc.), lorlatinib has shown a strong ability to penetrate the blood-brain barrier in clinical practice, which makes it more effective in the treatment of ALK-positive non-small cell lung cancer associated with brain metastasis. This property makes lorlatinib a more effective treatment option in the treatment of advanced lung cancer, especially in patients with brain metastases.

Lorlatinib is not limited to the treatment of non-small cell lung cancer, but has also shown potential in other cancers in some studies. For example, lorlatinib may also provide an effective treatment option for ALK-positive large cell lymphoma and other tumor types. However, its current main clinical application is still focused on the treatment of ALK-positive non-small cell lung cancer.

In general, lorlatinib is a highly effectiveALK-targeted drug. With its precise pharmacological effects and strong brain penetration ability, it has shown significant efficacy in patients with advanced lung cancer.

Keyword tags: lorlatinib, lorlatinib, ALK inhibitor, tyrosine kinase inhibitor, non-small cell lung cancer, brain metastasis, targeted therapy, tumor treatment, drug type, ALK positivity

Reference materials：https://go.drugbank.com/drugs/DB12130